Skip to main content
. Author manuscript; available in PMC: 2010 Aug 15.
Published in final edited form as: Cancer Res. 2009 Aug 4;69(16):6546–6555. doi: 10.1158/0008-5472.CAN-09-0605

Figure 2. The proteasome inhibitor bortezomib restores expression of FoxO3a and induces apoptosis in BCR-ABL transformed cells.

Figure 2

a) Quantitative cell survival data from annexin-V staining 24 hours after bortezomib treatment of BaF3/BCR-ABL cells. Data shown are averages +/- std. dev from three independent experiments. b) Western blot showing elevated FoxO3a protein expression with increasing concentrations of bortezomib. c) Western blot indicates an increase in FoxO3a expression in BaF3/BCRABL cells treated with bortezomib over a 24-hour time course. Values below the blot are determined by densitometry with β-ACTIN normalization. d) Western blot demonstrating an increase in FoxO3a protein in nuclear extracts from BaF3/BCR-ABL cells treated with bortezomib. Whole cell extract (WCE) from untreated cells is included as a control. Successful compartmentalization is indicated by a lack of HSP-90 detection in the nuclear extracts, with its positive detection in WCE and cytoplasmic extracts.